Last reviewed · How we verify
Jiashen Tablets
At a glance
| Generic name | Jiashen Tablets |
|---|---|
| Also known as | treatment group 1, treatment group 2, treatment group 3, treatment group 4, treatment group 5 |
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Tolerability and Pharmacokinetics of Jiashen Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jiashen Tablets CI brief — competitive landscape report
- Jiashen Tablets updates RSS · CI watch RSS
- Tasly Pharmaceutical Group Co., Ltd portfolio CI